SECsense Logo

Amicus Therapeutics, Inc. 8-K Report: Key Insights as of February 21, 2025

$FOLD
Form 8-K
Filed on: 2025-02-21
Source
Amicus Therapeutics, Inc. 8-K Report: Key Insights as of February 21, 2025

Based on the provided XML section of the financial report, here are the key insights:

  1. Entity Information:
  • Company Name: Amicus Therapeutics, Inc.
  • CIK: 0001178879
  • State of Incorporation: Delaware (DE)
  • IRS Employer Identification Number (EIN): 71-0869350
  • Address: 47 Hulfish Street, Princeton, NJ 08542
  • Phone Number: 609-662-2000
  1. Filing Details:
  • Form Type: 8-K (Current Report)
  • Filing Date: February 21, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.01
  • Ticker Symbol: FOLD
  • Exchange: NASDAQ
  1. Financial Period:
  • As of Date: February 21, 2025
  • Period Start Date: February 21, 2025
  • Period End Date: February 21, 2025
  1. Units of Measure:
  • Currency: USD
  • Shares: The report uses shares as a unit of measurement.

Insights:

  • The report indicates that Amicus Therapeutics is actively filing a current report, which often includes significant corporate events.
  • The company is publicly traded on NASDAQ, which could imply a level of regulatory scrutiny and compliance requirements.
  • The specific focus on the date of the filing (February 21, 2025) suggests that this report may contain timely information relevant to investors, such as updates on financial performance, management changes, or other critical developments.

Overall, the information provided is foundational for understanding the corporate structure and recent activities of Amicus Therapeutics, Inc. in relation to its financial reporting obligations.